This study highlights the potential application of neoadjuvant therapy of CBDCA and anti-PD-1 in TNBC patients, and the critical roles of CCL4 and CD103+ DC in CD8+ T cell priming and infiltration in the tumor microenvironment. This evidence concerns the gene CCL4 and neoplasm.